SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell-related therapeutics, today announced that
industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board
of Directors.


Dr. Kirkman has broad executive experience from several public biotechnology
companies. He currently serves as the President and Chief Executive Officer of
Oncothyreon Inc., an oncology company with a long-established interest in the
immunotherapy field. He previously held various executive positions at Xcyte
Therapies, another immunotherapy company, and Protein Design Labs. Dr. Kirkman
began his career as a clinician-scientist, holding various positions at Brigham
and Women's Hospital, Boston, including Chief, Division of Transplantation. Dr.
Kirkman holds an M.D. degree from Harvard Medical School and a B.A. in economics
from Yale University.


"We are delighted to welcome Dr. Kirkman to the Board of Directors. His
extensive expertise as a life science industry executive and a clinician, as
well as his in-depth knowledge of the capital markets, adds immeasurable value
to our company," stated Mr. David Allan, Stem Cell Therapeutics' Chairman.


In connection with the completion of the $33 million offering announced on
December 13, 2013, the Company issued 157,142,858 units at a price of $0.21
each. U.S.-based investors subscribed for approximately 97% of the issue. The
units consisted of either one common share and three-quarters of a common share
purchase warrant ("Common Share Units") or one Series 1 Non-Voting First
Preferred Share and three-quarters of a common share purchase warrant
("Preferred Share Unit"). Of the total Units issued, 79,247,693 units were
Common Share Units and 77,895,165 units were Preferred Shares Units. Each whole
warrant entitles the holder to purchase one common share at a price of $0.28 at
any time prior to expiry on December 13, 2018. Each preferred shareholder has
the right to convert all or any of their preferred shares into an equal number
of common shares, as adjusted for stock splits, certain distributions and other
fundamental transactions. The articles of amendment creating the new class of
preferred shares have been filed on Sedar at www.sedar.com. Following the
offering, the Company has 121,752,380 common shares issued and outstanding
(344,798,764 on a fully diluted basis).


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies.
Building on over half a century of leading and groundbreaking Canadian stem cell
research, the company is supported by established links to a group of prominent
Toronto academic research institutes and cancer treatment centers, representing
one of the world's most acclaimed cancer research hubs. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer
stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
Jeff Ramson/Kirin Smith
ProActive Capital
+1 646-863-6519
jramson@proactivecapital.com
ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From May 2024 to Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2023 to Jun 2024